Free Trial
NASDAQ:SCYX

SCYNEXIS (SCYX) Stock Price, News & Analysis

SCYNEXIS logo
$1.03 -0.01 (-0.96%)
Closing price 03/25/2025 04:00 PM Eastern
Extended Trading
$1.03 0.00 (0.00%)
As of 08:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About SCYNEXIS Stock (NASDAQ:SCYX)

Key Stats

Today's Range
$1.01
$1.04
50-Day Range
$0.86
$1.22
52-Week Range
$0.82
$3.07
Volume
39,323 shs
Average Volume
189,609 shs
Market Capitalization
$40.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Buy

Company Overview

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Remove Ads

SCYNEXIS Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
21st Percentile Overall Score

SCYX MarketRank™: 

SCYNEXIS scored higher than 21% of companies evaluated by MarketBeat, and ranked 844th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of SCYNEXIS is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of SCYNEXIS is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    SCYNEXIS has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about SCYNEXIS's valuation and earnings.
  • Percentage of Shares Shorted

    2.05% of the float of SCYNEXIS has been sold short.
  • Short Interest Ratio / Days to Cover

    SCYNEXIS has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in SCYNEXIS has recently decreased by 10.15%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    SCYNEXIS does not currently pay a dividend.

  • Dividend Growth

    SCYNEXIS does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.05% of the float of SCYNEXIS has been sold short.
  • Short Interest Ratio / Days to Cover

    SCYNEXIS has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in SCYNEXIS has recently decreased by 10.15%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    SCYNEXIS has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for SCYNEXIS this week, compared to 1 article on an average week.
  • MarketBeat Follows

    Only 2 people have added SCYNEXIS to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, SCYNEXIS insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.85% of the stock of SCYNEXIS is held by insiders.

  • Percentage Held by Institutions

    54.37% of the stock of SCYNEXIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about SCYNEXIS's insider trading history.
Receive SCYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter.

SCYX Stock News Headlines

SCYNEXIS (SCYX) to Release Earnings on Thursday
StockNews.com Downgrades SCYNEXIS (NASDAQ:SCYX) to Sell
Elon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to Mars
Musk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to help build human colonies on the Red Planet. And here on Earth? Optimus is about to change everything.
SCYNEXIS Full Year 2024 Earnings: Misses Expectations
See More Headlines

SCYX Stock Analysis - Frequently Asked Questions

SCYNEXIS's stock was trading at $1.21 at the start of the year. Since then, SCYX stock has decreased by 14.9% and is now trading at $1.03.
View the best growth stocks for 2025 here
.

SCYNEXIS, Inc. (NASDAQ:SCYX) posted its quarterly earnings data on Wednesday, March, 12th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.13. The firm had revenue of $0.98 million for the quarter. SCYNEXIS had a negative trailing twelve-month return on equity of 66.21% and a negative net margin of 425.41%.

SCYNEXIS's stock reverse split before market open on Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Top institutional investors of SCYNEXIS include Federated Hermes Inc. (7.63%), AMH Equity Ltd (1.65%), OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC (0.51%) and Northern Trust Corp (0.40%). Insiders that own company stock include Gonzalez David Angulo, Marco Taglietti and Scott Sukenick.
View institutional ownership trends
.

Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that SCYNEXIS investors own include Zomedica (ZOM), Jumia Technologies (JMIA), NIO (NIO), Nano Dimension (NNDM), Sorrento Therapeutics (SRNE), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

Last Earnings
3/12/2025
Today
3/26/2025
Next Earnings (Estimated)
3/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SCYX
Employees
60
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$67.04 million
Net Margins
-425.41%
Pretax Margin
-422.22%

Debt

Sales & Book Value

Annual Sales
$3.75 million
Cash Flow
$1.78 per share
Price / Cash Flow
0.58
Book Value
$1.96 per share
Price / Book
0.53

Miscellaneous

Free Float
36,867,000
Market Cap
$40.15 million
Optionable
Optionable
Beta
1.67

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:SCYX) was last updated on 3/26/2025 by MarketBeat.com Staff
From Our Partners